These results are consistent with the anti-HNSCC activity of SHP099 occurring through coinhibition of MAPK and PI3K pathways, and these two pathways being the key targets of SHP2 inhibition in sensitive HNSCCs. This evidence concerns the gene PTPN11 and head and neck squamous cell carcinoma.